Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - azomyr
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp49a6edf85307fce92cb7f88732583618
identifier: http://ema.europa.eu/identifier
/EU/1/00/157/001-013
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Azomyr 5 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-49a6edf85307fce92cb7f88732583618
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/00/157/001-013
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - azomyr
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
What Azomyr is
Azomyr contains desloratadine which is an antihistamine.
How Azomyr works
Azomyr is an antiallergy medicine that does not make you drowsy. It helps control your allergic reaction and its symptoms.
When Azomyr should be used
Azomyr relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older. These symptoms include sneezing, runny or itchy nose, itchy palate, and itchy, red or watery eyes.
Azomyr is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy). These symptoms include itching and hives.
Relief of these symptoms lasts a full day and helps you to resume your normal daily activities and sleep.
Do not take Azomyr
Warnings and precautions
Talk to your doctor, pharmacist or nurse before taking Azomyr:
Children and adolescents
Do not give this medicine to children less than 12 years of age.
Other medicines and Azomyr
There are no known interactions of Azomyr with other medicines.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Azomyr with food, drink and alcohol
Azomyr may be taken with or without a meal.
Use caution when taking Azomyr with alcohol.
Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Taking Azomyr is not recommended if you are pregnant or nursing a baby.
There is no data available on male/female fertility.
Driving and using machines
At the recommended dose, this medicine is not expected to affect your ability to drive or use machines. Although most people do not experience drowsiness, it is recommended not to engage in activities requiring mental alertness, such as driving a car or operating machinery until you have established your own response to the medicine.
Azomyr tablet contains lactose
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Use in adults and adolescents 12 years of age and over
The recommended dose is one tablet once a day with water, with or without food.
This medicine is for oral use.
Swallow the tablet whole.
Regarding the duration of treatment, your physician will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Azomyr. If your allergic rhinitis is intermittent (presence of symptoms for less than 4 days per week or for less than 4 weeks), your physician will recommend you a treatment schedule that will depend on the evaluation of the history of your disease. If your allergic rhinitis is persistent (presence of symptoms for 4 days or more per week and for more than 4 weeks), your physician may recommend you a longer term treatment.
For urticaria, the duration of treatment may be variable from patient to patient and therefore you should follow the instructions of your physician.
If you take more Azomyr than you should
Take Azomyr only as it is prescribed for you. No serious problems are expected with accidental overdose. However, if you take more Azomyr than you were told to, tell your doctor, pharmacist or nurse immediately.
If you forget to take Azomyr
If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule. Do not take a double dose to make up for a forgotten dose.
If you stop taking Azomyr
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
During the marketing of Azomyr, cases of severe allergic reactions (difficulty in breathing, wheezing, itching, hives and swelling) have been reported very rarely. If you notice any of these serious side effects, stop taking the medicine and seek urgent medical advice straight away.
In clinical studies in adults, side effects were about the same as with a dummy tablet. However, fatigue, dry mouth and headache were reported more often than with a dummy tablet. In adolescents, headache was the most commonly reported side effect.
In clinical studies with Azomyr, the following side effects were reported as:
Common: the following may affect up to 1 in 10 people
During the marketing of Azomyr, the following side effects were reported as:
Very rare: the following may affect up to 1 in 10,000 people
Not known: frequency cannot be estimated from the available data
unusual weakness
yellowing of the skin and/or eyes
increased sensitivity of the skin to the sun, even in case of hazy sun, and to UV light, for instance to UV lights of a solarium
changes in the way the heart beats
abnormal behaviour
aggression
weight increased, increased appetite
depressed mood
dry eyes
Children Not known: frequency cannot be estimated from the available data
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.
Do not store above 30 C. Store in the original package.
Do not use this medicine if you notice any change in the appearance of the tablets.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Azomyr contains
What Azomyr looks like and contents of the pack
Azomyr 5 mg film-coated tablet is light blue, round and embossed with elongated letters S and P
on one side and plain on the other. Azomyr 5 mg film-coated tablets are packed in blisters in packs of 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50 or 100 tablets. Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder:
N.V. Organon Kloosterstraat 6 5349 AB Oss The Netherlands
Manufacturer: Organon Heist bv, Industriepark 30, 2220 Heist-op-den-Berg, Belgium.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Organon Belgium T l/Tel: 0080066550123 (+32 2 2418100)
dpoc.benelux@organon.com
Lietuva Organon Pharma B.V. Lithuania atstovyb
Tel.: +370 52041dpoc.lithuania@organon.com
( . .) . . -
.: +359 2 806 3dpoc.bulgaria@organon.com
Luxembourg/Luxemburg Organon Belgium T l/Tel: 0080066550123 (+32 2 2418100)
dpoc.benelux@organon.com
esk republika Organon Czech Republic s.r.o. Tel.: +420 233 010 dpoc.czech@organon.com
Magyarorsz g Organon Hungary Kft. Tel.: +36 1 766 1dpoc.hungary@organon.com
Danmark Organon Denmark ApS Tlf: +45 4484 6info.denmark@organon.com
Malta Organon Pharma B.V., Cyprus branch Tel: +356 2277 8dpoc.cyprus@organon.com
Deutschland Organon Healthcare GmbH Tel: 0800 3384 726 (+49 (0) 89 2040022 10) dpoc.germany@organon.com
Nederland N.V. Organon Tel.: 00800 66550123 (+32 2 2418100) dpoc.benelux@organon.com
Eesti Organon Pharma B.V. Estonian RO Tel: +372 66 61 dpoc.estonia@organon.com
Norge Organon Norway AS Tlf: +47 24 14 56 info.norway@organon.com
N.V. Organon : +30-216 6008 sterreich Organon Austria GmbH Tel: +43 (0) 1 263 28 dpoc.austria@organon.com
Espa a Organon Salud, S.L. Tel: +34 91 591 12 organon_info@organon.com Polska Organon Polska Sp. z o.o. Tel.: +48 22 105 50 organonpolska@organon.com
France Organon France T l: +33 (0) 1 57 77 32 Portugal Organon Portugal, Sociedade Unipessoal Lda. Tel: +351 218705geral_pt@organon.com
Hrvatska Organon Pharma d.o.o. Tel: +385 1 638 4dpoc.croatia@organon.com
Rom nia Organon Biosciences S.R.L. Tel: +40 21 527 29 dpoc.romania@organon.com
Ireland Organon Pharma (Ireland) Limited Tel: +353 15828medinfo.ROI@organon.com
Slovenija Organon Pharma B.V., Oss, podru nica Ljubljana Tel: +386 1 300 10 dpoc.slovenia@organon.com
sland Vistor hf. S mi: +354 535 7Slovensk republika Organon Slovakia s. r. o. Tel: +421 2 44 88 98 dpoc.slovakia@organon.com
Italia Organon Italia S.r.l. Tel: +39 06 90259dpoc.italy@organon.com
Suomi/Finland Organon Finland Oy Puh/Tel: +358 (0) 29 170 3dpoc.finland@organon.com
Organon Pharma B.V., Cyprus branch : +357 22866dpoc.cyprus@organon.com
Sverige Organon Sweden AB Tel: +46 8 502 597 dpoc.sweden@organon.com
Latvija rvalsts komersanta Organon Pharma B.V.
p rst vniec ba Tel: +371 66968dpoc.latvia@organon.com
United Kingdom (Northern Ireland) Organon Pharma (UK) Limited Tel: +44 (0) 208 159 3medicalinformationuk@organon.com
This leaflet was last revised in <{MM/YYYY}><{month YYYY}>
Detailed information on this medicine is available on the European Medicines Agency website http://www.ema.europa.eu.
Package leaflet: Information for the patient
Azomyr 0.5 mg/ml oral solution
desloratadine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Entry 1 - fullUrl = Composition/composition-en-49a6edf85307fce92cb7f88732583618
Resource Composition:
Generated Narrative: Composition composition-en-49a6edf85307fce92cb7f88732583618
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/00/157/001-013status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - azomyr
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp49a6edf85307fce92cb7f88732583618
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp49a6edf85307fce92cb7f88732583618
identifier:
http://ema.europa.eu/identifier
/EU/1/00/157/001-013type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Azomyr 5 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en